Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.

PD-L2:138.6 ng/mL, PD-L1:111.7 ng/mL

Cetrelimab targets a human IgG4 κmonoclonal antibody to PD-1. Cetrelimab blocks the interaction of PD-1 with PD-L1 and PD-L2 (IC50 of 111.7 ng/mL and 138.6 ng/mL, respectively). The EC50 value of cetrelimab was 0.4138 μg/mL (HEK-293 cells), and the Kd of binding PD-1 was 1.72 nM (HEK293 cells). [1]

Cetrelimab (10 mg/kg, 21 days) reduced mean MC38 tumor volume in PD-1 knockin mice (hPD-1KI).
In a PDX lung mouse model, cetrelimab (10 mg/kg every 5 days for 6 cycles) increased the number of peripheral T cells and reduced the average tumor volume. [1]